Treatment of Psychiatric Disorders and Skin-Restricted Lupus Remission

Jalenques, Isabelle; Rondepierre, Fabien; Massoubre, Catherine; Labeille, B.; Perrot, Jean‐Luc; Mulliez, Aurélien; D’Incan, M.

doi:10.1001/jamadermatol.2017.3590

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, although our study does not show any link between alexithymia or impaired emotional awareness and SRL activity, relationships between alexithymia and poor compliance with medical treatment have been documented (44,45), In addition, our study shows that alexithymia can be associated with psychiatric disorders, which are highly prevalent in patients with SRL (2). Such disorders should therefore be screened for, in order to offer suitable additional treatment if needed, especially as it has been demonstrated that psychotropic drugs help in achieving remission of SRL in patients with psychiatric disorders (46). Three hypotheses could be considered with regard to the underlying mechanisms: first, lessdepressed patients may be more compliant with their dermatological treatment; secondly, if the SRL has a psychosomatic component, the less-depressed patients may be less responsive to stress and their dermatological disease more stable; and thirdly, antidepressants with anti-inflammatory properties may have an independent or additional effect on SRL (47).…”

Section: Discussionmentioning

confidence: 50%

Emotional Ability and Skin-restricted Lupus Evolution: A Longitudinal Study

Jalenques¹,

Rondepierre²,

Mulliez³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 50%

Emotional Ability and Skin-restricted Lupus Evolution: A Longitudinal Study

Jalenques¹,

Rondepierre²,

Mulliez³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

“…It is therefore necessary to identify patients at risk and to tailor their management so as to limit the occurrence of psychiatric disorders. Antidepressants, which are effective against depressive, anxious and somatic symptoms [ 18 ], could achieve this aim and at the same time, probably owing to their anti-inflammatory action, exert a beneficial effect on dermatological disorders [ 49 , 50 ]. Another study also showed that the CRP level could be taken into consideration in the choice of antidepressant [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

Psychiatric symptomatology in skin-restricted lupus patients without axis I psychiatric disorders: A post-hoc analysis

Rondepierre¹,

Tauveron-Jalenques²,

Valette³

et al. 2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Skin-restricted lupus is a chronic inflammatory disease associated with high rates of depression and anxiety disorders. Patients without psychiatric disorders can experience anxiety and depressive symptoms at a subclinical level, which could be risk factors for progression towards psychiatric disorders. It was decided, therefore, to investigate the presence of specific symptoms in skin-restricted lupus patients without axis I psychiatric disorders and their impact on the occurrence of axis I psychiatric disorders during the study follow-up. Methods Longitudinal data of 38 patients and 76 matched controls without active axis I psychiatric disorders from the LuPsy cohort were used. Depressive, neurovegetative, psychic and somatic anxiety symptom scores were established from the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating scale (HAMA). Results None of the participants had any current active axis I psychiatric disorders but the patients had personality disorders more frequently and had received more past psychotropic treatments than the controls. They also had higher MADRS and HAMA scores than the controls, in particular neurovegetative, psychic anxiety and somatic symptoms scores. No dermatological factor tested was associated with these scores, whereas being a lupus patient was associated with higher neurovegetative and somatic symptoms scores, having a current personality disorder with higher depressive and neurovegetative scores and receiving more past psychotropic treatments with psychic anxiety and somatic symptoms scores. The occurrence of psychiatric disorders during the study follow-up was associated with an elevated psychic anxiety score at baseline and past psychotropic treatment but not with history of psychiatric disorder. Limitations The LuPsy cohort included a large number of patients with axis I psychiatric disorders, the sample without axis I psychiatric disorders is therefore limited. Conclusions We observed numerous psychiatric symptoms among the skin-restricted lupus patients. They should therefore receive special attention in the management of their subclinical symptoms before they progress towards full psychiatric disorders.

show abstract